CALL/NOVO-NORDISK B/1400/0.01/19.12.25 | Real-time BOERSE MUENCHEN 01:55:26 28/05/2024 pm IST | ||
| 0.06 EUR | -1.64% |
|
| Current month | -10.29% | ||
| 1 month | +1.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.06 | -1.64% |
| 27/24/27 | 0.061 | -3.17% |
| 24/24/24 | 0.063 | -5.97% |
| 23/24/23 | 0.067 | +11.67% |
| 22/24/22 | 0.06 | -3.23% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 01:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG7D9T |
| ISIN | DE000GG7D9T9 |
| Date issued | 22/04/2024 |
| Strike | 1,400 kr |
| Maturity | 19/12/2025 (571 Days) |
| Parity | 100 : 1 |
| Emission price | 0.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.068 € |
|---|---|
| Lowest since issue | 0.049 € |
| Spread | 0.05 € |
| Spread % | 45.45% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
919.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.14%
- Stock Market
- Warrants
- Warrant
